PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction.
- Author:
Zheng XU
1
;
Rui-Peng JIA
1
Author Information
1. Department of Urology, Nanjing Hospital of Nanjing Medical University / Nanjing First Hospital, Nanjing, Jiangsu 210006, China.
- Publication Type:Journal Article
- Keywords:
erectile dysfunction;
lower urinary tract symptoms;
phosphodiesterase 5;
benign prostatic hyperplasia
- MeSH:
Aged;
Drug Therapy, Combination;
Erectile Dysfunction;
complications;
drug therapy;
Humans;
Lower Urinary Tract Symptoms;
complications;
drug therapy;
Male;
Phosphodiesterase 5 Inhibitors;
therapeutic use;
Prostatic Hyperplasia;
complications;
drug therapy;
Quality of Life
- From:
National Journal of Andrology
2018;24(4):355-359
- CountryChina
- Language:Chinese
-
Abstract:
Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is a common disease with frequent occurrence in elderly men, and its incidence shows a significant positive correlation with age. Evidence has confirmed that BPH/LUTS is closely related to erectile dysfunction (ED) and significantly affects the quality of life of elderly males. Phosphodiesterase 5 inhibitors (PDE5i) can improve both ED and BPH/LUTS of the patients and PDE5 is expected to be a new therapeutic target for BPH/LUTS with ED. This review explores the structure and function of PDE5 and the action mechanisms of PDE5i so as to provide a more effective strategy for the clinical treatment of BPH/LUTS with ED.
